Literature DB >> 31404031

Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner.

Rui Ren1,2,3, Jie Yu4, Yan Zhang1, Sheng-Fei Wang1, Xia Guo4, Meng Shen1, Meng-Dan Xu1, Min Jiang1, Qiaoming Zhi3, Kai Chen1, Min Tao1, Meng-Yao Wu1, Dong-Mei Gu4, Wei Li1,5.   

Abstract

OBJECTIVE: Identify the molecular mechanism of inflammatory stimuli induced pancreatic cancer progression.
METHODS: RNA-seq, microarray assay and bioinformatics analyses were used to identify differentially expressed genes. Immunohistochemical staining was performed to evaluate CD68, CD163, β-catenin, CD103, CCL3 markers. Quantitative real-time polymerase chain reaction (qRT-PCR), luciferase reporter assay, apoptosis assay, wound healing assay and immunofluorescence were performed to study the relationship of inflammatory stimuli and WNT/β-catenin pathway.
RESULTS: Differentially expressed genes of macrophage-conditioned medium-treated pancreatic cancer cells were related with WNT/β-catenin pathway. Inflammatory stimuli could activate WNT/β-catenin signaling pathway. In 106 pancreatic cancer patients, nuclear β-catenin expression of CD68-high group was much higher than CD68-low group (P < 0.05), as same as CD163 (P < 0.05). Inflammatory stimuli downregulated the expression of CCL3 via WNT/β-catenin pathway and inhibited the chemotaxis of CD103 dendritic cells. Six pancreatic cancer prognosis associating genes were upregulated by inflammatory stimuli via WNT/β-catenin pathway. Transforming growth factor-β promoted malignant biological behavior of pancreatic cancer cells through WNT/β-catenin pathway-dependent mechanism.
CONCLUSIONS: Our present study provided a novel mechanism involved in the inflammation-driven cancer progression through tumor immune escape and downstream gene regulation of WNT/β-catenin pathway-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31404031     DOI: 10.1097/MPA.0000000000001386

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Diabetes mellitus type 2 drives metabolic reprogramming to promote pancreatic cancer growth.

Authors:  Guermarie Velazquez-Torres; Enrique Fuentes-Mattei; Hyun Ho Choi; Sai-Ching J Yeung; Xiangqi Meng; Mong-Hong Lee
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-05-27

2.  Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease.

Authors:  Joo-Hyun Park; Jung Yong Hong; Kyungdo Han; Wonseok Kang; Joo Kyung Park
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

Review 3.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.

Authors:  Jan Korbecki; Szymon Grochans; Izabela Gutowska; Katarzyna Barczak; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

4.  Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway.

Authors:  Chaoxiong Zhang; Lei Huang; Jingyuan Xiong; Linshen Xie; Shi Ying; You Jia; Yuqin Yao; Xuejiao Song; Zhenguo Zeng; Jialing Yuan
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

5.  Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies.

Authors:  Miguel A Ortega; Leonel Pekarek; Oscar Fraile-Martinez; Cielo Garcia-Montero; Miguel A Saez; Angel Asúnsolo; Miguel A Alvarez-Mon; Jorge Monserrat; Lidia Ruiz-Llorente; Natalio García-Honduvilla; Agustin Albillos; Julia Buján; Melchor Alvarez-Mon; Luis G Guijarro
Journal:  Curr Oncol       Date:  2022-03-30       Impact factor: 3.109

6.  Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer.

Authors:  Hongkai Zhuang; Zixuan Zhou; Zuyi Ma; Zhenchong Li; Chunsheng Liu; Shanzhou Huang; Chuanzhao Zhang; Baohua Hou
Journal:  J Cell Mol Med       Date:  2020-10-18       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.